MedPath

Cabergoline

Cabergoline Tablets

Approved
Approval ID

c85d676c-e23e-468d-9de3-79202d9fad3f

Product Type

HUMAN PRESCRIPTION DRUG LABEL

Effective Date

Jan 18, 2020

Manufacturers
FDA

A-S Medication Solutions

DUNS: 830016429

Products 1

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

Cabergoline

PRODUCT DETAILS

NDC Product Code50090-3951
Application NumberANDA076310
Marketing CategoryC73584
Route of AdministrationORAL
Effective DateNovember 12, 2019
Generic NameCabergoline

INGREDIENTS (5)

CABERGOLINEActive
Quantity: 0.5 mg in 1 1
Code: LL60K9J05T
Classification: ACTIB
CITRIC ACID MONOHYDRATEInactive
Code: 2968PHW8QP
Classification: IACT
CROSCARMELLOSE SODIUMInactive
Code: M28OL1HH48
Classification: IACT
MAGNESIUM STEARATEInactive
Code: 70097M6I30
Classification: IACT
MICROCRYSTALLINE CELLULOSEInactive
Code: OP1R32D61U
Classification: IACT

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

Cabergoline - FDA Drug Approval Details